Immatics präsentiert umfangreiche präklinische Daten für bispezifischen TCR-Kandidaten IMA402 gegen die Zielstruktur PRAME auf der Jahrestagung der Europäischen Gesellschaft für Medizinische Onkologie (ESMO)
September 10, 2022 03:06 ET
|
Immatics N.V.
IMA402 ist ein bispezifischer TCR-Kandidat (T cell engaging receptor, TCER®) der nächsten Generation mit verlängerter Halbwertszeit, der gegen ein HLA-A*02:01-präsentiertes Peptid des Antigens PRAME...
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
September 10, 2022 03:06 ET
|
https://immatics.com/
TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced...
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
September 10, 2022 03:00 ET
|
Anaveon
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
Florida Cancer Specialists & Research Institute Physicians Present Cancer Care Advancements at Global Oncology Gathering
September 08, 2022 12:30 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the latest cutting-edge developments and findings...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 07, 2022 18:05 ET
|
Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022
September 06, 2022 14:37 ET
|
NKGen Biotech
SANTA ANA, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine
August 09, 2022 08:00 ET
|
Predicine
SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine....
NGS Sample Preparation Market Size is projected to reach USD 5.38 Billion by 2030, growing at a CAGR of 14.32%: Straits Research
July 27, 2022 11:50 ET
|
Straits Research
New York, United States, July 27, 2022 (GLOBE NEWSWIRE) -- The next-generation sequencing (NGS) industry is growing because of technologies that verify high-quality gene libraries and sequencing...
SHEPHERD Therapeutics Presents First Public Data at 2021 ESMO Congress Highlighting Ability of DELVE Computational Approach to Optimize Therapeutic Selection for Cancer Patients
September 16, 2021 07:00 ET
|
SHEPHERD Therapeutics
BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for cancer patients, is pleased to present an e-poster of results from a...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
September 16, 2021 02:45 ET
|
MacroGenics, Inc.
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor...